Systemic sclerosis (SSc) is a systemic autoimmune disease in which inflammation and fibrosis play a crucial role and lead to severe damage and failure of multiple organs such as the skin, joints, tendons, gastrointestinal tract, lungs, heart, blood vessels, and kidneys. It primarily affects women (female:male ratio of 4:1-10:1, depending on age and ethnicity), and there are two clinical subsets according to the extent of skin involvement: diffuse cutaneous SSc (dcSSc) (skin damage proximal to elbows and/or knees or that affects thorax and/or abdomen at any given time during the disease) and limited cutaneous SSc (lcSSc). This disease may lead to major disabilities due to vascular complications, cardiopulmonary involvement, inflammatory myopathy, and arthritis. In addition, it can cause malnutrition due to gastrointestinal tract involvement, and it can decrease quality of life as a consequence of the psychological and social impact.
COVID-19 scenario analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs such as hydroxychloroquine have seen huge boost in demand for the management of COVID-19. Increase in demand for drugs has been witnessed, which is likely to offer lucrative opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the industry include the off-label use of drugs approved for symptomatic indications, such as rheumatoid arthritis. Availability of lesser curative therapies and increase in prevalence of off-label drug use are underlying factors boosting the industry to gain traction in the next few years. In addition, the development of targeted biologics and small molecule combination therapies propels the industry growth. Furthermore, surge in prevalence of scleroderma and increase in incidence of genetic mutations coupled with drastic changes in the environment are anticipated to augment the market growth during the forecast period. However, unfavorable reimbursement scenario hinders the growth of the industry.
Product approvals to boost the market
There has been an increase in the number of product approvals by the FDA which would help the industry to gain trajectory phase in the next coming years. For instance, in September 2019, the U.S. FDA approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.
It is the first FDA-approved treatment for this rare lung condition. Patients suffering from scleroderma need effective therapies, and the FDA supports the efforts of drug companies that are designing and conducting the clinical trials necessary to make treatment options available for scleroderma patients. Nintedanib is now a treatment option to slow the rate of decline in pulmonary function in patients who have interstitial lung disease from scleroderma.
Surge in number of mergers and acquisitions
Increase in the number of mergers and acquisitions is anticipated to help the industry boost in the coming years. For instance, in October 2020, a U.S. pharma major, Eli Lilly announced that it acquired privately held Disarm Therapeutics, which is creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm discovered novel, potent SARM1 inhibitors and is advancing them in pre-clinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
Key benefits of the report:
- This study presents the analytical depiction of the global scleroderma therapeutics industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global scleroderma therapeutics market share
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions answered in the global scleroderma therapeutics market research report:
- Which are the leading players active in the global scleroderma therapeutics market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in tasking further strategic steps?
Scleroderma Therapeutics Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Indication |
|
 By Region |
|
 Key Market Players | Bristol-Myers Squibb Company,, Prometic Life Sciences Inc.,, F. Hoffman La Roche,, Akashi Therapeutics,, arGentis Pharmaceuticals, LLC,, Boehringer Ingelheim International GmbH,, Cytori Therapeutics Inc.,, CORPORATION,, Kadmon Holdings, Inc.,, Emerald Health Pharmaceuticals, |
Loading Table Of Content...
